IC-OS Weekly Webinar - Tough Clinical Cases in Cardio-Oncology

Dr. Brion Randolph is a hematologic oncologist and stem cell transplant physician at the University of Tennessee Health Science Center (UTHSC) in Memphis. He specializes in the care of patients with blood cancers with an interest in leukemia, myeloproliferative disorders, myelodysplastic syndromes and high-risk multiple myeloma. He joined the faculty at UTHSC in December 2019 and has practiced in the field of hematology and medical oncology since 2009. Before joining the team at UTHSC, Dr. Randolph was a member of the faculty at the Medical University of South Carolina (MUSC) in Charleston. He has also served as the chief of oncology and medical director for the hematologic malignancies program at Cancer Treatment Centers of America (CTCA) in Atlanta, GA, where he held an adjunct faculty position at the Morehouse School of Medicine in Atlanta. Prior to CTCA, Dr. Randolph was the medical director for the Kirkland Cancer Center in Jackson, Tennessee, where he was the principal investigator for the center’s clinical research through the Vanderbilt Ingram Cancer Center Affiliates Network and Eastern Cooperative Oncology Group. Dr. Randolph earned his medical degree from the University of South Carolina in Columbia, and he is board certified in medical oncology, hematology and internal medicine. He completed residency training in internal medicine at Baylor College of Medicine in Houston, Texas, where he also completed his fellowship training in hematology and oncology. He subsequently received his training in stem cell transplant and cellular therapy at The University of Texas MD Anderson Cancer Center. Dr. Randolph joined the faculty at UTHSC to become part of a team of experts looking to find the cure for blood cancers. His research interests include the molecular biology of cancer, cellular immunotherapy and health care disparities. He believes that the road to finding a cure is through a combination of clinical trials, scientific research and treating the whole person while also empowering patients with the knowledge and understanding of their disease and treatment options. Dr. Randolph has raised over $100,000 for cancer research through the Leukemia and Lymphoma Society (LLS) Man and Woman of the Year Campaign and Team in Training program. He has also served on the Board of Trustees for the Georgia Chapter of LLS.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Edith Pituskin is an associate professor at University of Alberta, Edmonton, Canada.

A director, cardio-oncology at Methodist Le Bonheur Healthcare, Memphis, Tennessee, US. Features in 1 video on Wondr Medical. Isaac Rhea generally speaks on Cardio-Oncology, Cardio-Oncology, and Oncology.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

A cardiologist at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, New York, US. Features in 1 video on Wondr Medical. Robert Copeland Halperin generally speaks on Cardio-Oncology, Cardio-Oncology, and Oncology.